Hongda Liu1, Zheng Gong2, Kangshuai Li3, Qun Zhang4, Zekuan Xu5, Yunfei Xu6. 1. Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. 2. The Jackson Laboratory, Bar Harbor, ME, 04609, USA. 3. Department of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China. 4. Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. 5. Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. xuzekuan@njmu.edu.cn. 6. Department of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China. xuyunfei1988@126.com.
Abstract
BACKGROUND: The Mnk2 kinase, encoded by MKNK2 gene, plays critical roles in MAPK signaling and was involved in oncogenesis. Human MKNK2 pre-mRNA can be alternatively spliced into two splicing isoforms, the MKNK2a and MKNK2b, thus yielding Mnk2a and Mnk2b proteins with different domains. The involvement of Mnk2 alternative splicing in colon cancer has been implicated based on RNA-sequencing data from TCGA database. This study aimed at investigating the upstream modulators and clinical relevance of Mnk2 alternative splicing in colon adenocarcinoma (CAC). METHODS: PCR, western blotting and immunohistochemistry (IHC) were performed to assess the expression of Mnk2 and upstream proteins in CAC. The function of Mnk2 and its regulators were demonstrated in different CAC cell lines as well as in xenograft models. Two independent cohorts of CAC patients were used to reveal the clinical significance of MKNK2 alternative splicing. RESULTS: Comparing with adjacent nontumorous tissue, CAC specimen showed a decreased MKNK2a level and an increased MKNK2b level, which were correlated with KRAS mutation and tumor size. The SRSF1 (serine/arginine-rich splicing factor 1) was further confirmed to be the major splicing factor targeting MKNK2 in CAC cells. Higher expression of SRPK1/2 or decreased activity of PP1α were responsible for enhancing SRSF1 phosphorylation and nucleus translocation, subsequently resulted in a switch of MKNK2 alternative splicing. CONCLUSIONS: Our data showed that phosphorylation and subcellular localization of SRSF1 were balanced by SRPK1/2 and PP1α in CAC cells. High nucleus SRSF1 promoted MKNK2 splicing into MKNK2b instead of MNK2a, consequently enhanced tumor proliferation.
BACKGROUND: The Mnk2 kinase, encoded by MKNK2 gene, plays critical roles in MAPK signaling and was involved in oncogenesis. HumanMKNK2 pre-mRNA can be alternatively spliced into two splicing isoforms, the MKNK2a and MKNK2b, thus yielding Mnk2a and Mnk2b proteins with different domains. The involvement of Mnk2 alternative splicing in colon cancer has been implicated based on RNA-sequencing data from TCGA database. This study aimed at investigating the upstream modulators and clinical relevance of Mnk2 alternative splicing in colon adenocarcinoma (CAC). METHODS: PCR, western blotting and immunohistochemistry (IHC) were performed to assess the expression of Mnk2 and upstream proteins in CAC. The function of Mnk2 and its regulators were demonstrated in different CAC cell lines as well as in xenograft models. Two independent cohorts of CAC patients were used to reveal the clinical significance of MKNK2 alternative splicing. RESULTS: Comparing with adjacent nontumorous tissue, CAC specimen showed a decreased MKNK2a level and an increased MKNK2b level, which were correlated with KRAS mutation and tumor size. The SRSF1 (serine/arginine-rich splicing factor 1) was further confirmed to be the major splicing factor targeting MKNK2 in CAC cells. Higher expression of SRPK1/2 or decreased activity of PP1α were responsible for enhancing SRSF1 phosphorylation and nucleus translocation, subsequently resulted in a switch of MKNK2 alternative splicing. CONCLUSIONS: Our data showed that phosphorylation and subcellular localization of SRSF1 were balanced by SRPK1/2 and PP1α in CAC cells. High nucleus SRSF1 promoted MKNK2 splicing into MKNK2b instead of MNK2a, consequently enhanced tumor proliferation.
Entities:
Keywords:
Alternative splicing; Colon adenocarcinoma; MKNK2; SRPK1/2; SRSF1
Authors: Raoni Pais Siqueira; Mônica Maria Magalhães Caetano; Luciana Ângelo de Souza; Patrícia Maria Siqueira Dos Passos; Natália Borges Simaroli; Marcus Vinícius de Andrade Barros; Ana Paula Martins de Souza; Leandro Licursi de Oliveira; Abelardo Silva-Júnior; Juliana Lopes Rangel Fietto; Róbson Ricardo Teixeira; Felipe Roberti Teixeira; Gustavo Costa Bressan Journal: Toxicol In Vitro Date: 2020-01-18 Impact factor: 3.500
Authors: Pedro Serrano; Brandon E Aubol; Malik M Keshwani; Stefano Forli; Chen-Ting Ma; Samit K Dutta; Michael Geralt; Kurt Wüthrich; Joseph A Adams Journal: J Mol Biol Date: 2016-04-15 Impact factor: 5.469
Authors: Jianling Xie; Kaikai Shen; Ashley T Jones; Jian Yang; Andrew R Tee; Ming Hong Shen; Mengyuan Yu; Swati Irani; Derick Wong; James E Merrett; Roman V Lenchine; Stuart De Poi; Kirk B Jensen; Paul J Trim; Marten F Snel; Makoto Kamei; Sally Kim Martin; Stephen Fitter; Shuye Tian; Xuemin Wang; Lisa M Butler; Andrew C W Zannettino; Christopher G Proud Journal: Cell Mol Life Sci Date: 2020-03-13 Impact factor: 9.261
Authors: Konstantinos Tzelepis; Etienne De Braekeleer; Demetrios Aspris; Isaia Barbieri; M S Vijayabaskar; Wen-Hsin Liu; Malgorzata Gozdecka; Emmanouil Metzakopian; Hamish D Toop; Monika Dudek; Samuel C Robson; Francisco Hermida-Prado; Yu Hsuen Yang; Roya Babaei-Jadidi; Dimitrios A Garyfallos; Hannes Ponstingl; Joao M L Dias; Paolo Gallipoli; Michael Seiler; Silvia Buonamici; Binje Vick; Andrew J Bannister; Roland Rad; Rab K Prinjha; John C Marioni; Brian Huntly; Jennifer Batson; Jonathan C Morris; Cristina Pina; Allan Bradley; Irmela Jeremias; David O Bates; Kosuke Yusa; Tony Kouzarides; George S Vassiliou Journal: Nat Commun Date: 2018-12-19 Impact factor: 14.919